Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Authors
Keywords
-
Journal
CANCER
Volume 123, Issue 10, Pages 1791-1799
Publisher
Wiley
Online
2016-12-27
DOI
10.1002/cncr.30490
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
- (2015) Nicholas C. P. Cross et al. ANNALS OF HEMATOLOGY
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
- (2014) Daniel Levin et al. DIABETOLOGIA
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha
- (2013) Rabab M. El Eit et al. INTERNATIONAL JOURNAL OF CANCER
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
- (2011) J.-C. Chomel et al. BLOOD
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic Myeloid Leukemia: A Historical Perspective
- (2010) John M. Goldman SEMINARS IN HEMATOLOGY
- Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
- (2008) Rihab Nasr et al. NATURE MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started